Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients

NCT05438498 is registered in ClinicalTrials.gov with MediMergent, LLC as lead sponsor.

NCT NCT05438498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05438498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients
Lead sponsor
MediMergent, LLC
Phase
Phase 3
Overall status
Terminated
Start date
June 3, 2022
Completion date
June 30, 2023
Enrollment
550 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection